The breast cancer-associated protein, BARD1, colocalizes with BRCA1 in nuclear foci in the S phase and after DNA damage, and the two proteins form a stable heterodimer implicated in DNA repair, protein ubiquitination, and control of mRNA processing. BARD1 has a BRCA1-independent proapoptotic activity; however, little is known about its regulation. Here, we show that BARD1 localization and apoptotic activity are regulated by nuclear-cytoplasmic shuttling. We identified a functional CRM1-dependent nuclear export sequence (NES) near the N-terminal RING domain of BARD1. The NES forms part of the BRCA1 dimerization domain, and coexpression of BRCA1 resulted in masking of the NES and nuclear retention of BARD1. In transient expression assays, BARD1 apoptotic activity was stimulated by nuclear export, and both apoptotic function and nuclear export were markedly reduced by BRCA1. Similar findings were obtained for endogenous BARD1. Silencing BRCA1 expression by siRNA, or disrupting the endogenous BARD1/BRCA1 interaction by peptide competition caused a reduction in BARD1 nuclear localization and foci formation, and increased the level of cytoplasmic BARD1 correlating with increased apoptosis. Our findings suggest that BRCA1/BARD1 heterodimer formation is important for optimal nuclear targeting of BARD1 and its role in DNA repair and cell survival.
Introduction
The BRCA1-associated RING domain protein (BARD1) is the dominant binding partner of the breast and ovarian cancer susceptibility protein 1 (BRCA1) in living cells (reviewed in Baer and Ludwig, 2002) . BARD1 and BRCA1 show a remarkable degree of structural similarity in that they both harbor an aminoterminal RING finger domain and a tandem array of BRCA1 carboxy-terminal (BRCT) domains (Miki et al., 1994; Wu et al., 1996) . There is now a considerable body of evidence pointing to BARD1 as a key regulator of BRCA1 stability, localization and function. First, the two proteins are coordinately expressed throughout Xenopus laevis development in different cell types and tissues, and act to stabilize one another (Joukov et al., 2001) . BARD1 and BRCA1 colocalize in S-phasespecific nuclear dots (Jin et al., 1997) ; after DNA damage, they redistribute within the nucleus to form larger foci that contain DNA repair factors including Rad51, PCNA, and BRCA2, suggesting a role for the two proteins in DNA repair and/or replication (Scully et al., 1997; Baer and Ludwig, 2002; Fabbro et al., 2002) . Furthermore, in biochemical experiments the two proteins cofractionate in a variety of DNA repair-associated nuclear complexes (Chiba and Parvin, 2001) .
Recently, the BARD1/BRCA1 complex was shown to interact with the RNA polymerase II holoenzyme (Chiba and Parvin, 2002) . Together with the finding that the heterodimer associates with the polyadenylation factor CstF-50 (Kleiman and Manley, 1999) , this may help to explain how BARD1/BRCA1 complexes inhibit mRNA processing in DNA-damaged cells (Kleiman and Manley, 2001) . The RING finger domain of BRCA1 has ubiquitin E3 ligase activity, which is ablated by tumorassociated missense mutations (Lorick et al., 1999; Ruffner et al., 2001) , but dramatically stimulated when BRCA1 and BARD1 form a heterodimeric complex (Hashizume et al., 2001; Baer and Ludwig, 2002) . The BARD1/BRCA1 dimer was also found to possess autoubiquitination activity in vitro (Chen et al., 2002) . Our laboratory recently discovered that BARD1 can promote nuclear import of BRCA1 and inhibit BRCA1 nuclear export by masking its nuclear export signal (NES) (Fabbro et al., 2002) . This 'chaperone' activity required a direct interaction between the two proteins, and BARD1 was found to stimulate recruitment of BRCA1 to DNA repair-associated nuclear foci after DNA damage (Fabbro et al., 2002) .
There is increasing evidence that BARD1 itself is a possible tumor suppressor protein, largely based on reports that detected both somatic as well as germ-line mutations in the BARD1 gene in a subset of breast, ovarian, and uterine cancers (Thai et al., 1998) . In particular, BARD1 gene mutations were identified in hereditary breast and ovarian tumors from patients who were negative for BRCA1 and BRCA2 gene alterations (Ghimenti et al., 2002) . Moreover, there is some experimental evidence from antisense RNA studies that repression of BARD1 expression in murine mammary epithelial cells resulted in phenotypic changes reminiscent of premalignancy (Irminger-Finger et al., 1998) . Recently, BARD1 was shown to induce apoptosis in mouse embryo fibroblasts via a pathway dependent on p53, but not requiring BRCA1 (Irminger-Finger et al., 2001) .
Given the protein domain similarity between BRCA1 and BARD1, and our preliminary observations that showed a variable nuclear-cytoplasmic distribution of transiently expressed and cellular BARD1, we tested the possibility that BARD1 subcellular localization might be regulated by shuttling between the nucleus and cytoplasm. We report here that BARD1 is indeed a nuclear-cytoplasmic shuttling protein. It contains an N-terminal NES, which facilitates nuclear export through the CRM1 transport receptor pathway. Analogous to the BRCA1 NES (Rodriguez and Henderson, 2000; Fabbro et al., 2002) , the BARD1 NES is also located directly within the BARD1-BRCA1-binding domain, and its export activity is blocked upon interaction with BRCA1, resulting in nuclear anchorage of BARD1. We describe a unique example of protein regulation, in which BRCA1 and BARD1 regulate the subcellular localization of one another through the reciprocal masking of their respective nuclear export signals. Furthermore, we present data that suggest that nuclear export of BARD1 contributes to its apoptotic function, and that this is reduced by BRCA1 through nuclear retention of BARD1.
Results

BARD1 shuttles between the nucleus and cytoplasm
To determine the subcellular distribution of endogenous BARD1, we prepared fractionated cell lysates from MCF-7 and T47D human breast cancer cells and HBL-100 human breast epithelial cells, and analysed them for BARD1 by Western blotting (Figure 1a ). The efficiency of the fractionation was verified by staining for topoisomerase II as a nuclear marker, and a-tubulin as a cytoplasmic marker (data not shown). Staining with a BARD1-specific antibody revealed that BARD1 was present mostly in the nuclear fraction, and also displayed some cytoplasmic staining in all cell lines (Figure 1a) . To test the possibility that BARD1, like its main binding partner BRCA1 (Rodriguez and Henderson, 2000) , is able to shuttle in and out of the nucleus, we overexpressed the CRM1 nuclear export receptor in T47D cells and examined its effect on BARD1 subcellular localization (Figure 1b ). In agreement with the Western blots, endogenous BARD1 displayed strong staining in the nuclei of untransfected T47D cells as determined by immunofluorescence microscopy. The transient expression of YFP-CRM1 caused a specific decrease in nuclear BARD1 and a relative increase in cytoplasmic BARD1 staining compared to YFP (Figure 1b) . Overexpression of YFP-CRM1 also increased the proportion of cells displaying no BARD1 staining, suggesting a possible link between BARD1 export and its degradation (Joukov et al., 2001) . Quantification of the BARD1 subcellular distribution patterns is shown (right panel) as the mean7s.d. from three experiments, where BARD1 is nuclear (nuc), nuclear and cytoplasmic (nuc/cyt), predominantly cytoplasmic (cyt), or not visible by staining (neg). (c) Effect of CRM1 overexpression, or inhibition of CRM1 by LMB treatment, on ectopic BARD1 localization in MCF-7 breast cancer cells. Graphs show the mean values7s.d. from at least three independent experiments (n, number of cells counted). Cells were scored as nuclear (N), nuclear and cytoplasmic (NC), or cytoplasmic (C), respectively. The unambiguous detection of ectopic BARD1 (arrowheads) relative to endogenous BARD1 when using anti-BARD1 antisera is shown by images taken at two different exposures (right panel) We next assessed ectopically expressed BARD1 for nuclear-cytoplasmic shuttling ability, by transiently expressing a BARD1 plasmid in MCF-7 cells followed by immunofluoresence microscopy ( Figure 1c ). Positive cells were scored as nuclear, nuclear/cytoplasmic, or cytoplasmic, respectively. Ectopic BARD1 was predominantly found in the nucleus of B45% of transfected cells, was nuclear/cytoplasmic in a similar proportion of cells, and was exclusively cytoplasmic in only 10% of cells. Cotransfection of YFP did not alter this localization profile. In contrast, coexpression of the CRM1 export receptor shifted ectopic BARD1 completely to the cytoplasm in 75% of cells, while treatment with the CRM1 export inhibitory drug, leptomycin B (LMB), induced nuclear accumulation of BARD1 (Figure 1c) . LMB treatment induced a nuclear shift in both Flag-or YFP-tagged BARD1 in transfected T47D and MCF-7 cells. Similarly in T47D cells, coexpression of CRM1 shifted ectopic BARD1 to the cytoplasm (data not shown). These results demonstrate that BARD1 is a nuclear-cytoplasmic shuttling protein regulated by CRM1-dependent nuclear export.
Identification of a highly active NES near the N-terminus of BARD1
To map the sequence responsible for BARD1 nuclear export, we created a series of N-and C-terminally truncated forms of BARD1 (Flag-tagged) and determined their subcellular localization (Figures 2a and b) . When the RING domain was removed from BARD1, the truncated protein (aa 95-777) was shifted significantly toward the cytoplasm. However, further Nterminal deletion extending beyond the RING domain (aa 171-777) caused BARD1 to localize almost exclusively to the nucleus (Figure 2b ). To further support these observations with biochemical data, we transfected YFP-tagged forms of BARD1- into MCF-7 cells, prepared nuclear and cytoplasmic cell fractions, and analysed the expression pattern of the ectopic proteins by Western blotting (Figure 2c ). These YFP-tagged forms of BARD1 displayed a distribution similar to the untagged forms when examined by fluorescence microscopy (data not shown). In good agreement with the above findings, Western blot analysis detected the RING domain deletion ) predominantly in the cytoplasmic fraction, whereas the more extensively truncated protein ) accumulated in the nuclear fraction (Figure 2c ). Furthermore, after treatment of cells with LMB, was shifted to the nucleus with more than 85% of the protein in the nuclear fraction. Taken together, the deletion mapping indicated a potential NES between amino acids 95 and 171, a conclusion supported by the observation that an Nterminal, RING finger containing BARD fragment (aa 1-188) displayed predominantly cytoplasmic staining (Figure 2b) .
A search for potential NESs within this region of BARD1 revealed the presence of two overlapping HIV-1 Rev-type NES sequences (see Henderson and Eleftheriou, 2000) , characterized by a cluster of large hydrophobic residues, preferentially leucines or isoleucines (Figure 3a ). Using a previously described GFP-based nuclear export assay (Henderson and Eleftheriou, 2000) , we tested these sequences for export activity. The Rev(1.4)-GFP fusion, an export signal-deficient protein that provides a negative control, remained in the nucleus of most transfected T47D cells even when Rev NLSmediated nuclear import was blocked by actinomycin D (Figure 3b ). As a positive control, insertion of the protein kinase inhibitor (PKI) NES into this vector resulted in effective nuclear export of GFP to the cytoplasm, as previously shown (Henderson and Eleftheriou, 2000) . The two BARD1 sequences tested in this assay promoted nuclear export of the fusion protein to very different extents. While NES1 (aa 92-111) displayed only weak nuclear export activity (assigned a rating of 1 þ in a scale of 1-9 þ where 9 þ is the highest), NES2 (aa 102-120) was highly active and led to cytoplasmic accumulation of the chimeric protein in Figure 3b ). The NES2 sequence showed optimal activity in this assay with a rating of 9 þ on a comparative scale, and its potent activity was mediated through the CRM1 export receptor as indicated by its sensitivity to LMB (Figure 3b ).
Defining critical residues in the BARD1 nuclear export signal
The BARD1 NES2 sequence shows a high degree of evolutionary conservation, with four potentially critical leucines located at corresponding positions of the BARD1 gene in other species (Figure 4a ). However, the spacing between the hydrophobic residues fails to meet exactly the CRM1-responsive NES consensus sequence of LX 3 LX 2 LXL (Bogerd et al., 1996; Henderson and Eleftheriou, 2000) . To identify those residues important for nuclear export activity, we tested a series of mutated NES constructs (fusing the NES to pRev(1.4)-GFP) bearing single or double amino acid changes of leucine to alanine (Figure 4b and L 114 residues were crucial for nuclear export. These findings prompted us to assess how the same NES point mutations affect nuclear transport when introduced into full-length BARD1.
Mutation of NES2 impairs nuclear export of BARD1
The BARD1 NES2 maps to the binding interface of BARD1 with BRCA1 (Brzovic et al., 2001a) . To minimize the risk of interference with the BRCA1 interaction, we introduced by site-directed mutagenesis the single amino-acid substitutions L 107 A and L
114
A into full-length BARD1 (Figure 5a ). When transiently expressed in MCF-7 cells, the two NES point mutations induced a strong nuclear accumulation of full-length BARD1 (Figure 5b ; similar results seen with YFPtagged BARD1). To confirm that the NES mutations blocked CRM1-dependent nuclear export of full-length BARD1, we cotransfected the BARD1 constructs with YFP-tagged CRM1. Strikingly, while wild-type BARD1 was efficiently exported to the cytoplasm by CRM1, the NES mutants were almost unaffected by CRM1 NESs from PKI and BRCA1. The NES activity was scored from þ 1 (low activity) to þ 9 (maximum activity) and is summarized at the right. (b) NES2 displayed very strong export activity in a transfection-based nuclear export assay. The respective sequences were cloned into a Rev-GFP fusion vector (1.4-GFP), transiently transfected into T47D cells, and the subcellular localization of GFP was determined in the presence or absence of actinomycin D (ActD), which retards Rev-GFP nuclear import (Henderson and Eleftheriou, 2000) . Where indicated, cells were treated with LMB to abrogate nuclear export via CRM1. The NES-deficient 1.4-GFP construct was used as a negative control (not showing any export activity, set to '0'). The PKI NES was a positive control. Graphs represent the mean values of two independent experiments, with the s.d. not exceeding 15% overexpression, and retained a predominantly nuclear staining pattern ( Figure 5c ).
To exclude the possibility that the NES point mutations had induced a profound nuclear retention of BARD1, rather than abolish nuclear export, we introduced a well-defined, heterologous NES from the Ran-binding protein (RanBP1) into the C-terminal part of the export-defective L 107 A BARD1 mutant (see L107A þ NES in Figure 5a ), and examined whether nuclear export could be recovered. Indeed, we found that the introduction of the RanBP1 NES resulted in a subcellular distribution of the L107A þ NES protein very similar to that of wild-type BARD1 (Figure 5b) . Furthermore, CRM1-dependent nuclear export was restored by the heterologous NES, as more than 70% of cells showed exclusively cytoplasmic BARD1 staining when YFP-CRM1 was coexpressed (Figure 5c , right panel). In conclusion, BARD1 contains a potent NES that is primarily responsible for the CRM1-dependent nuclear export of BARD1, and whose activity can be silenced by a single amino-acid mutation.
Site-directed mutations in NES2 do not disrupt binding of BARD1 to BRCA1
To show that the L 107 A and L
114
A point mutations did not induce conformational changes in BARD1 that were indirectly responsible for the block to nuclear export, we examined whether the BARD1 NES mutants were still able to bind BRCA1, a feature that is highly dependent on correct folding at the N-terminus of both proteins (Brzovic et al., 2001a, b) . We have shown previously that the BRCA1 splice variant (D306-1312), which lacks the NLS-containing exon 11, can enter the nucleus in an NLS-independent manner via its interaction with BARD1 (Fabbro et al., 2002) . We exploited this observation to establish a unique assay to test whether the BARD1 NES mutants had retained their capacity to interact with BRCA1 in vivo. The different forms of BARD1 were cotransfected with BRCA1(D306-1312) and the localization of BRCA1(D306-1312) was examined ( Figure 5d ). We found that both wild-type and NES-mutated forms of BARD1 were able to shift cytoplasmic BRCA1 (D306-1312) exclusively to the nucleus in 490% of transfected cells, indicative of direct binding. Thus, NES point mutations specifically blocked the nuclear export of BARD1 without altering its interaction with BRCA1.
BRCA1 anchors BARD1 in the nucleus by masking the BARD1 NES
The NMR solution structure of the BARD1/BRCA1 dimer resolved a binding interface comprising two pairs of antiparallel a-helical coils that flank the RING motifs of each protein (Brzovic et al., 2001a, b) . As illustrated Figure 4 Mutational analysis of NES2 identified residues critical for nuclear export activity. (a) BARD1 NES2 amino-acid sequence is conserved between different species. Conserved leucine residues typical of CRM1-dependent NESs are boxed. (b) Various mutations were introduced in the NES sequence, converting isoleucine or leucine to alanine at the indicated positions, and cloned into the 1.4-GFP vector to test their effect on nuclear export. Cell images shown (in bottom panel) are typical of the various BARD1 NES-GFP fusions following transfection into T47D cells. The relative export activities were determined as described in the legend to Figure 3 . Leucines 107 and 114 were found to be critical for export activity in Figure 6a , we previously identified an NES in BRCA1 that maps precisely to one of the BRCA1 a-coils (helix 3) within the binding pocket (NES, residues 81-99; Rodriguez and Henderson, 2000) . We now report that the BARD1 NES2 sequence also corresponds to one of these a-coils within the four-helix dimeric interface (see Figure 6a ). The helical position of those critical NES residues mapped in BARD1 and BRCA1 was compared by protein modeling, based on the NMR structure (Figure 6a, right-hand panel) . The key hydrophobic amino acids face inward at the binding interface, and most were reported buried within the BRCA1/BARD1-binding site (Brzovic et al., 2001a) . These observations implied that the BARD1 NES might become masked upon heterodimerization with BRCA1, as we had previously shown for the BRCA1 NES (Fabbro et al., 2002) .
To test this hypothesis for BARD1, we examined the influence of BRCA1 on BARD1 subcellular distribution in MCF-7 cells. The coexpression of BRCA1 elicited a major shift to the nucleus in BARD1 (Figure 6b ), similar to that observed by mutation of the NES2 sequence. On the other hand, a BRCA1 deletion mutant that lacks the N-terminal BARD1 interaction domain (D1-170) did not enhance nuclear localization of BARD1 (data not shown). Similarly, a BARD1 truncation mutant missing the N-terminal RING finger region (aa 95-777), and that is predominantly found in the cytoplasm, was not shifted to the nucleus by BRCA1 and did not colocalize with BRCA1 (Figure 6c ). Thus, BRCA1-dependent regulation of BARD1 localization requires the RING finger-containing sequences that help mediate the interaction between these two proteins.
Does BRCA1 trap BARD1 in the nucleus by masking its NES? To address this question, we first coexpressed CRM1 with BARD1 and BRCA1, and discovered that the addition of BRCA1 blocked the ability of CRM1 to export BARD1 from the nucleus to the cytoplasm (Figure 6b ). This observation is consistent with BRCA1 masking of the BARD1 NES sequence. To confirm this hypothesis, we tested the effect of BRCA1 on localization of the BARD1(L107A þ NES) mutant in which the NES was relocated to the C-terminus. BRCA1 was still capable of interacting with the L107A þ NES mutant (as suggested by the data for L107A shown in Figure 5d ), but it did not significantly alter the subcellular localization of the BARD1 mutant (Figure 6b ). Furthermore, CRM1-dependent nuclear export of the L107A þ NES mutant occurred efficiently even in the presence of BRCA1 (Figure 6b ). Taken together, these results indicate that the ability of BRCA1 to trap BARD1 in the nucleus is dependent on the position of the BARD1 NES, and is consistent with a role for BRCA1 masking of the BARD1 export signal. Figure 5 Point mutations in NES2 abrogate nuclear export of full-length BARD1. (a) Single amino-acid substitutions were introduced into full-length BARD1 to create the NES mutants 2 (L107A) and 3 (L114A). L107A þ NES was created by inserting the functional RanBP1 NES into the C-terminus of the L107A NES mutant. (b) Immunofluorescence images of ectopic wild-type and mutated BARD1 following transfection into MCF-7 cells, detected using BARD1 antisera (see Materials and methods). Graphs show the nuclear/cytoplasmic distribution as mean values7s.d. from at least three independent experiments. (c) The indicated forms of BARD1 were cotransfected into MCF-7 cells with YFP-tagged CRM1 and the subcellular distribution was determined by immunofluorescence microscopy. Graphs show scoring results from three independent experiments. (d) Mutation of the NES specifically affects nuclear export, not interaction with BRCA1. The different BARD1 expression vectors were cotransfected with an exon 11-deficient BRCA1 that does not contain any NLS and localizes to the cytoplasm (left image). As revealed by the typical cell images shown, the BARD1 NES mutants were equally as capable of binding to BRCA1(D306-1312) and transporting it into the nucleus as was wild-type BARD1
Reducing BRCA1 levels by RNA interference alters BARD1 subcellular distribution Previous studies have demonstrated a concordance between expression levels of BRCA1 and BARD1 (Joukov et al., 2001) , and in p53 À/À mouse embryos the knockdown of either protein impairs the expression of its binding partner in vivo (McCarthy et al., 2003) . While we cannot exclude a link between nuclear export and degradation of these proteins, we have never observed a clear stabilizing effect of LMB (CRM1 inhibitor) on BRCA1/BARD1 protein levels in T47D or MCF-7 cells. To test the influence of cellular BRCA1 on BARD1 nuclear localization, we reduced BRCA1 levels by transfecting siRNA constructs into T47D cells. In this cell line, BRCA1 silencing by an siRNA (but not a mutant control sequence) was quite efficient as determined by immunofluorescence microscopy and scoring of YFP-positive cells (Figure 7a ). We analysed transfected cells for the localization and expression of endogenous BARD1, and found that cells with reduced BRCA1 displayed either a loss of BARD1 or a consistent (but incomplete) shift in its location from the nucleus to the cytoplasm (see Figure 7b) . As BARD1 retains its shuttling activity and can interact with other nuclear factors (Chiba and Parvin, 2002; Spahn et al., 2002) , we did not expect to see a complete cytoplasmic relocalization of BARD1 in the absence of BRCA1. These findings represent the first physiological evidence that BRCA1 can regulate BARD1 nuclear localization, and are consistent with a role in NES masking. The BRCA1 siRNA also reduced, but did not abolish, the level of BARD1 S-phase nuclear dots (Figure 7c ), revealing that BRCA1 contributes to, but is not essential for BARD1 recruitment to nuclear foci.
A link between BARD1 nuclear export and its apoptotic function
We next investigated the functional consequence of BARD1 nuclear export and its regulation by BRCA1. The only BARD1 function independent of BRCA1 yet identified is a p53-dependent proapoptotic activity, observed after the induction of BARD1 by genotoxic stress (Irminger-Finger et al., 2001) . Interestingly, BARD1-dependent apoptosis was partially decreased (Brzovic et al., 2001a) , showing BARD1 (blue), BRCA1 (red), and their respective nuclear export signals (NESs; green). The position of key NES residues identified for BARD1 (this study) and BRCA1 (Rodriguez and Henderson, 2000) is shown (magenta) in the zoom image at right, and the conservation of protein domains in the lower panel. Images were generated using Protein Explorer (version 1.982) from published data files (Brzovic et al., 2001a) . (b) The ability of BRCA1 to block CRM1-mediated export of BARD1 was tested by transfection of BARD1 (wild-type or L107A þ NES mutant), BRCA1, and CRM1 constructs into MCF-7 cells. Cell images and distribution profiles show that BRCA1 blocks export of wild-type BARD1, but not BARD1 containing a repositioned NES. by BRCA1 in mouse embryo stem cells (Irminger-Finger et al., 2001) , and it was suggested that BARD1 was responsible for mediating the p53-dependent apoptosis previously observed in BRCA1-targeted mice (Xu et al., 2001) . We tested whether silencing BRCA1 by siRNA affected apoptosis in different cell lines, and observed a small but consistent twofold increase in apoptosis in HBL-100 cells (Figure 8a ) and U2OS cells (not shown), but not in T47D cells, which express mutant p53 (data not shown). The observed apoptosis correlated with enhanced cytoplasmic staining of BARD1. To further assess whether cellular BRCA1 influences BARD1 nuclear export and apoptotic activity, we transfected YFP or YFP-tagged N-terminal BARD1 fragments comprising amino acids 1-96 and 1-127 into MCF-7 cells and compared their impact on BARD1 localization and apoptosis. Of these plasmids, only BARD1(1-127) is capable of binding to BRCA1 (Brzovic et al., 2001a) , and thus when overexpressed in cells should compete for endogenous BRCA1 and disrupt the BRCA1/BARD1 dimer. In transfected cells, the YFP-BARD1(1-127) fragment caused a pronounced shift in BARD1 to the cytoplasm compared to YFP-BARD1(1-96) and YFP (Figure 8b) , and likewise caused a marked increase in apoptosis as measured by Hoechst staining of nuclei. An important point to note is that almost all of the apoptotic cells observed displayed cytoplasmic BARD1, or a loss of BARD1 expression.
To test the possibility that BARD1 apoptotic activity is linked to its nuclear export, we overexpressed fulllength wild-type and NES-mutated forms of BARD1 in MCF-7 cells and scored for apoptosis by Hoechst staining (Figure 8c ) or by flow cytometry (Figure 8d ). BARD1-induced apoptosis was inhibited 460% by coexpression of BRCA1 or B50% by mutations in the BARD1 NES. To show that the NES mutations did not affect apoptosis indirectly, we tested the plasmid pBARD1(L107A þ NES) containing a repositioned NES at the C-terminus and found that apoptotic activity was recovered (Figure 8c ). Moreover, BARD1 (L107A þ NES), which is not retained in the nucleus by BRCA1 (see Figure 6b) , was not inhibited in its apoptotic function by BRCA1, indicating that the antiapoptotic action of BRCA1 is mediated through its ability to mask the BARD1 NES. BARD1 proapoptotic activity was far less pronounced in p53-mutant T47D cells, consistent with previous observations of p53-dependency in mouse cells (Irminger-Finger et al., 2001) , but nonetheless was still reduced by NES mutations in T47D cells. The above findings, when considered together, suggest that BARD1 localization is regulated by nuclear export in vivo, and that nuclear export stimulates BARD1 apoptotic activity. We propose that BRCA1 inhibits BARD1 apoptotic function at least partly through masking of the BARD1 NES, and that the nuclear entrapment of BRCA1/ BARD1 complexes is important for cell survival, in addition to its presumed role in DNA repair (Baer and Ludwig, 2002) .
Discussion
BARD1 has a proapoptotic activity previously linked to its induced expression in mouse cells following genotoxic stress (Irminger-Finger et al., 2001) . The apoptotic activity previously observed was dependent on p53, and partly suppressed by coexpression of BRCA1 in mouse TAC-2 mammary cells and embryo stem cells (IrmingerFinger et al., 2001) . In this study, we confirm a similar regulation for ectopic and endogenous human BARD1 in breast cancer cells, and identify a possible mechanism for the antiapoptotic action of BRCA1 through its regulation of BARD1 nuclear export. We demonstrate for the first time that BARD1 subcellular localization and apoptotic function are regulated by nuclearcytoplasmic shuttling. We define a functional nuclear export sequence at the N-terminus of BARD1 within the BRCA1-binding domain, and show that heterodimerization with BRCA1 masks the export signal causing nuclear retention of BARD1 and reducing its apoptotic activity. Furthermore, disrupting the endogenous BARD1/BRCA1 interaction by peptide competition induced a cytoplasmic shift in cellular BARD1 and an increase in apoptosis, supporting the in vivo regulation of BARD1 by BRCA1.
BARD1 has been labeled a putative tumor suppressor due to observations that its gene is mutated in a subset of breast, ovarian, and uterine cancers (Thai et al., 1998; Ghimenti et al., 2002) . The major link between BARD1 and breast/ovarian cancer reflects the strong and stable interaction between BARD1 and BRCA1, which colocalize in the nucleus (Jin et al., 1997; Scully et al., 1997) and form complexes that can be purified from living cells (Baer and Ludwig, 2002; Chiba and Parvin, 2001 ). To date, most published BARD1 activities relate to its effects on BRCA1, which has been far more intensively studied. BARD1 can promote nuclear localization of BRCA1 (Fabbro et al., 2002) , stimulate its localization to nuclear sites of DNA repair (Fabbro et al., 2002) , and the two proteins when bound together as a heterodimer acquire ubiquitin E3 ligase activity (Hashizume et al., 2001; Ruffner et al., 2001) , become more stable (Joukov et al., 2001; Hashizume et al., 2001) and exert a possible effect on mRNA processing (Kleiman and Manley, 1999) . BARD1 also displays a remarkably similar domain structure to BRCA1 (N-terminal RINGs and C-terminal tandem BRCT domains), and recent 127) . Only the latter fusion peptide can dimerize with BRCA1, and thus act as a competitor fragment to disrupt the endogenous BRCA1/BARD1 interaction in cells. At 48 h post-transfection, cells were stained for cellular BARD1 and for apoptotic nuclei (Hoechst). The % cells displaying an increase in cytoplasmic BARD1 is shown, and the cytoplasmic shift induced by YFP-BARD1(1-127) correlated with increased apoptosis. (c) The above data were suggestive of a link between BARD1 nuclear export (or degradation) and apoptotic function. To directly test the role of nuclear export, we transfected wild-type BARD1 and NES mutant forms of BARD1 into cells and compared apoptotic activity 48 h later by Hoechst staining of nuclei (MCF-7 cells). Equivalent expression levels of transiently expressed BARD1 were confirmed by Western blots probed with anti-FLAG antibody, and stained for Topoisomerase II as a loading control. (d) YFP-BARD1 fusion constructs were also compared for apoptotic activity in MCF-7 (p53-positive) and T47D cells (p53-mutant) by flow cytometry. The assays showed that NES mutations reduced BARD1 apoptotic activity, as did cotransfection of BRCA1 evidence from gene knockout experiments in mice by Ludwig and colleagues indicates roles for both BRCA1 and BARD1 in maintaining genomic stability (McCarthy et al., 2003) .
In this study, we reveal an additional and unexpectedly sophisticated level of reciprocal regulation for BRCA1 and BARD1, relating to their subcellular localization. The previous NMR structure of the BRCA1/BARD1 heterodimer showed that the association is governed by contacts between two pairs of ahelices that flank the RING domains of each protein (Brzovic et al., 2001a, b) . We recently discovered in BRCA1 that one of the a-helical coils in the dimerization domain is an active nuclear export signal (Rodriguez and Henderson, 2000) , and that BARD1 promotes BRCA1 nuclear localization by masking the NES (Fabbro et al., 2002) . Here, we have described a functional NES in BARD1 located at the same relative position (C-terminal to the RING domain) as the BRCA1 NES, and corresponding to another of the acoils within the dimerization domain (see Figure 6a) . Thus, BRCA1 and BARD1 are independently capable of shuttling between the nucleus and cytoplasm when they are not bound to one another; however, their association leads to reciprocal masking of their respective export signals and traps the heterodimer in the nucleus. To our knowledge, no other pair of heterodimeric-binding partners has been reported to exhibit this type of subcellular regulation. These findings may explain why BARD1 and BRCA1 are usually detected in the cell nucleus in vivo, but can be induced to exit the nucleus by overexpression of the CRM1 export receptor (Figure 1 , and Rodriguez and Henderson, 2000) , or when their interaction is disrupted by peptide competition ( Figure 8 and Fabbro et al., 2002) .
BARD1 itself differs from BRCA1 in that it contains a set of Ankyrin type repeats (of as yet unknown function), and has been shown to interact with the Ewings family tumor gene product (EWS) and its tumor-associated fusion product, EWS-FLI1 (Spahn et al., 2002) . This interaction involves the BARD1 Cterminus, which should remain accessible even when BARD1 is dimerized with BRCA1. It will prove interesting to test whether free BARD1 exports EWS or EWS-FLI1 from the nucleus, or whether it affects EWS-FLI1 transcriptional activity. The search for other novel BARD1-binding partners remains in its infancy. The mechanism of BARD1 nuclear import is still to be determined, although our mapping data suggest that a possible NLS(s) is located after amino-acid position 177 (Figure 2) . We observed no effect on shuttling by the commonly reported BARD1 mutation Q564H, which previously was thought to affect the role of BARD1 in mRNA processing (Kleiman and Manley, 2001) . This is perhaps not surprising since this mutation is quite distant from the NES and was reported not to interfere with the binding of BRCA1 (Kleiman and Manley, 2001) .
The other distinguishing feature of BARD1 is that, unlike BRCA1, its proapoptotic activity is stimulated by p53 (Irminger-Finger et al., 2001; Figure 8c ). We devised a range of experimental approaches that support a role for NES-dependent transport in the apoptotic function of BARD1. It is unlikely that this shift in localization is absolutely critical to apoptotic function, in that blocking nuclear export did not completely abolish apoptosis, but reduced it to 50%. However, a very clear correlation was observed between cytoplasmic, but not nuclear, staining of BARD1 and cell death. We suggest that nuclear export contributes to BARD1-mediated apoptosis, and that this process is regulated through dimerization with BRCA1. It is possible that BARD1 acts in the cytoplasm, binding a cytoplasmic structure/ protein required for the apoptotic process, or that it must first enter the nucleus prior to binding and exporting an apoptosis-inhibitory factor from the nucleus. Alternatively, nuclear localization of BARD1 may directly inhibit an apoptosis-stimulating factor, which is activated upon export of BARD1. This latter possibility could also relate to the DNA repair function of BARD1/BRCA1, and a DNA breakage-induced signaling of apoptosis when BARD1 is absent from the nucleus. Experiments to further define the mechanistic links between BARD1 nuclear transport and cell death are underway. Finally, we note that BRCA1/ BARD1 complexes have been widely implicated in different aspects of DNA repair, and the two proteins colocalize at nuclear sites of DNA repair and replication (Jin et al., 1997; Scully et al., 1997; Fabbro et al., 2002) . Our findings (Rodriguez and Henderson, 2000; Fabbro et al., 2002; and this study) indicate that the strict nuclear compartmentalization of BRCA1/BARD1 dimers correlates very well with both DNA repair activity and with prolonged cell survival. We predict that specific cellular signals, possibly associated with the DNA damage checkpoint, might trigger dissociation of the BRCA1/BARD1 complex and thereby lead to a nuclear export-associated pathway for cell death.
Materials and methods
Cell culture and transfections
MCF-7 and T47D breast cancer cells and HBL-100 human breast epithelial cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum (FCS) under standard conditions. Transfections were performed at 50% confluency with 2 mg of DNA using lipofectamine2000 (Invitrogen). At 6 h post-transfection, the transfection mixture was removed and replaced with DMEM containing 10% FCS, and after 32-48 h cells were fixed and processed for fluorescence microscopy, flow cytometry, or cell fractionation. When required, LMB was added at a final concentration of 6 ng/ml for 6 h prior to processing.
Plasmid construction
Construction of the expression vectors pF-BARD1, pF-BARD1(95-777), pF-BRCA1, pF-BRCA1(D1-170), pF-BRCA1(D306-1312), pF-CRM1, pYFP-CRM1, and pF-YFP was described previously (Rodriguez and Henderson, 2000; Fabbro et al., 2002) . pF-BARD1(1-188) was created by replacing a PstI/XbaI or AflII/XbaI fragment, respectively, of pF-BARD1 by linker sequences (introducing early stop sites). To construct pF-BARD1(171-777), an NotI/NheI fragment of pF-BARD1 was replaced by PCR fragments generated with the following primers: JR39(forward): 5 0 -TACTAA GCGGCCGCCAAAGATGCAAGTGCTC-3 0 and JR41 (reverse): 5 0 -CTGTTGTTCTGAAGACAG-3 0 . The NES mutations (L107A and L114A) were introduced into the BARD1 cDNA by a PCR-based site-directed mutagenesis strategy. pF-L107A þ NES was created by inserting into the NheI site of pF-BARD1(L107A) in-frame, a short DNA duplex coding for the RanBP1 NES, which was prepared by annealing the following oligonucleotides: (MF10: 5 0 -CTAGCCATG CCGAAAAAGTCGCGGAAAAGCTAGAAGCTC TCTCGGTGAAGGAGGAGACCG-3 0 and MF11: 5 0 -CTAG CGGTCTCCTCCTTCACCGAGAGAGCTTCTAGCTTTT CCGCGACTTTTTCGGCATGG-3 0 ). The integrity of all constructs was confirmed by sequencing.
The BARD1 siRNA constructs were made by inserting two consecutive DNA fragments between the ApaI and EcoRI sites of the vector pBS/U6 (Sui et al., 2002) , which drives the expression of short 21-nt hairpin siRNAs following transfection into mammalian cells. The insert sequences were as follows: a wild-type target sequence in BRCA1 (5 0 -GGCCTTCACAGTGTCCTTTAA-3 0 ) and a matched mutant negative control (5 0 -GGCCTTCAGTGTGTCGATTAA-3 0 ; mutated residues in bold) sequence. The competition plasmids YFP-BARD1(1-96) and YFP-BARD1(1-127) were made by PCR-amplifying BARD1 N-terminal fragments from pF-BARD1 using the forward primer 5 0 -GATCTCGAGCT-CAAATGCCGGATAATCGGCAG-3 0 (start site in bold) and the reverse primers 5 0 -GACTGCAGAATTCTT-CAAGTCTTGTATCCAG-3 0 (for 1-96) and 5 0 -GACTGCA-GAATTCGGTTTATCTTCTTTCAAATCTG-3 0 (for 1-127). The PCR fragments were digested with SacI and EcoRI and cloned into EYFP-C1 (Clontech).
RNA-mediated interference
RNA-mediated interference (RNAi) of BRCA1 expression was mediated by transient expression of pBS/U6 siRNA constructs (Sui et al., 2002) . Cells were cotransfected with a YFP marker and the indicated pBS/U6 constructs. After 48 h, the effect on endogenous BRCA1 expression levels was determined by immunofluorescence microscopy using anti-BRCA1 monoclonal antibody Ab4 (Oncogene Research), and the results scored by two different investigators each using 'blinded' sample scoring in three different experiments.
Nuclear export assay
The in vivo export assay using the Rev(1.4)-GFP reporter system was performed as described previously (Henderson and Eleftheriou, 2000) . Briefly, DNA fragments encoding the different amino-acid sequences to be tested for export activity were inserted into the BamHI/AgeI digested pRev(1.4)-GFP plasmid. T47D cells were transfected with the different NESconstructs and processed for fluorescence microscopy 32 h later. Where indicated, nuclear import was inhibited by the addition of actinomycin D for the last 4 h before fixation at a concentration of 5 mg/ml. To inhibit CRM1-dependent nuclear export, LMB was added for 4 h prior to fixation at a concentration of 6 ng/ml.
Immunofluorescence microscopy and imaging
Fixing of cells and immunostaining was performed as described (Fabbro et al., 2002) . YFP-tagged proteins were detected directly following fixation, washing, and mounting.
Ectopic as well as endogenous BARD1 was detected using the polyclonal antibodies 699D (Jin et al., 1997) or 59L (a kind gift from Dr Richard Baer), diluted 1 : 1000. BRCA1 was detected using the monoclonal antibody Ab-4 (Oncogene Research) diluted 1 : 150. Bound antibodies were detected with either FITC-conjugated or biotin-conjugated secondary antibodies (Santa Cruz). In the latter case, this was followed by incubation with Texas red-avidin D (Vector Laboratories). Nuclei were counter-stained with the DNA dye Hoechst 33285 (Sigma). The subcellular localization of each protein was determined by scoring cells with an Olympus BX40 epifluorescence microscope. Images were captured with a 'SPOT' digital camera. Quantification of fluorescence was carried out using the Image pro software.
Measuring apoptosis by flow cytometry or Hoechst staining of nuclei
At 48 h post-transfection, YFP-transfected cells were fixed and permeabilized in 2% paraformaldehyde/0.1% nonidet NP-40 in PBS for 20 min at room temperature, then washed three times in PBS. Cells were detached using a cell scraper and resuspended in 800 ml of PBS containing RNase A (50 mg/ml) and propidium iodide (PI; 50 mg/ml). YFP-expressing cells were gated and the apoptosis profiles were determined using a Becton Dickinson Flow Cytometer. The percentage of apoptosis in each sample was determined by quantifying the sub-G1 nuclear DNA content using Cellquest software. Alternatively, cell nuclei were counterstained with the chromosome dye Hoechst 33285 (Sigma). The subcellular localization and percentage of cells with chromatin condensation (a marker of apoptosis) was determined for each ectopic protein by scoring cells with an Olympus BX40 epifluorescence microscope.
Cell fractionation and immunoblotting
Cells were separated into nuclear and cytoplasmic fractions using the NE-PER kit (Pierce). Cell extracts were then denatured at 951C for 5 min in sample buffer (100 mM Tris (pH 6.8), 20% glycerol, 0.01% bromophenolblue, 10% bmercaptoethanol, 5% SDS), and equal cellular amounts (B10 mg of nuclear extract and 30 mg of cytoplasmic extract) were separated on a 7.5% SDS-polyacrylamide gel, and transferred onto nitrocellulose membranes (Millipore). The membranes were treated in blocking solution (5% dry milk in PBS containing 0.2% Tween 20) and incubated with primary antibody overnight at 41C, followed by incubation with HRPconjugated secondary antibody (1 : 3000; Sigma). Endogenous BARD1 was detected with antibody 699D at 1 : 1000 dilution; ectopic forms of YFP-tagged BARD1 were detected with a monoclonal antibody against GFP (1 : 1000; Sigma). Topoisomerase II was detected with monoclonal antibody Ab-1 (Oncogene) used at a 1 : 200 dilution. Proteins were visualized by ECL (Amersham Biosciences). Prestained broad range molecular weight marker (BioRad) was used as molecular size standard.
